nodes	percent_of_prediction	percent_of_DWPC	metapath
Esomeprazole—Barrett's esophagus—head and neck cancer	0.933	1	CtDrD
Esomeprazole—ATP4A—larynx—head and neck cancer	0.00189	0.572	CbGeAlD
Esomeprazole—Rabeprazole—CYP1A1—head and neck cancer	0.000972	0.391	CrCbGaD
Esomeprazole—ATP4B—Ion transport by P-type ATPases—ATP7B—head and neck cancer	0.000812	0.229	CbGpPWpGaD
Esomeprazole—Omeprazole—CYP1A1—head and neck cancer	0.000792	0.318	CrCbGaD
Esomeprazole—Lansoprazole—CYP1A1—head and neck cancer	0.000725	0.291	CrCbGaD
Esomeprazole—ATP4A—Ion transport by P-type ATPases—ATP7B—head and neck cancer	0.000724	0.204	CbGpPWpGaD
Esomeprazole—ATP4A—neck—head and neck cancer	0.000502	0.152	CbGeAlD
Esomeprazole—Rash erythematous—Docetaxel—head and neck cancer	0.000365	0.00633	CcSEcCtD
Esomeprazole—Angina pectoris—Vinblastine—head and neck cancer	0.000361	0.00625	CcSEcCtD
Esomeprazole—ATP4A—connective tissue—head and neck cancer	0.00036	0.109	CbGeAlD
Esomeprazole—Otitis media—Docetaxel—head and neck cancer	0.000359	0.00622	CcSEcCtD
Esomeprazole—Necrosis—Docetaxel—head and neck cancer	0.000356	0.00617	CcSEcCtD
Esomeprazole—Oesophagitis—Fluorouracil—head and neck cancer	0.000354	0.00613	CcSEcCtD
Esomeprazole—Breast disorder—Hydroxyurea—head and neck cancer	0.000353	0.00612	CcSEcCtD
Esomeprazole—Rash maculo-papular—Fluorouracil—head and neck cancer	0.000352	0.0061	CcSEcCtD
Esomeprazole—Pancytopenia—Vinblastine—head and neck cancer	0.000352	0.00609	CcSEcCtD
Esomeprazole—Ageusia—Docetaxel—head and neck cancer	0.000345	0.00598	CcSEcCtD
Esomeprazole—Rigors—Docetaxel—head and neck cancer	0.000342	0.00593	CcSEcCtD
Esomeprazole—ATP4A—epithelium—head and neck cancer	0.000342	0.103	CbGeAlD
Esomeprazole—Pancreatitis—Hydroxyurea—head and neck cancer	0.000331	0.00574	CcSEcCtD
Esomeprazole—Depression—Vinblastine—head and neck cancer	0.000329	0.0057	CcSEcCtD
Esomeprazole—Eye irritation—Docetaxel—head and neck cancer	0.000327	0.00567	CcSEcCtD
Esomeprazole—Pancytopenia—Hydroxyurea—head and neck cancer	0.000321	0.00556	CcSEcCtD
Esomeprazole—Photosensitivity—Fluorouracil—head and neck cancer	0.00032	0.00555	CcSEcCtD
Esomeprazole—Swelling—Fluorouracil—head and neck cancer	0.000319	0.00552	CcSEcCtD
Esomeprazole—Dysuria—Hydroxyurea—head and neck cancer	0.000316	0.00547	CcSEcCtD
Esomeprazole—Neutropenia—Hydroxyurea—head and neck cancer	0.000316	0.00547	CcSEcCtD
Esomeprazole—Bone disorder—Docetaxel—head and neck cancer	0.00031	0.00536	CcSEcCtD
Esomeprazole—Agranulocytosis—Vinblastine—head and neck cancer	0.000308	0.00534	CcSEcCtD
Esomeprazole—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.000307	0.00533	CcSEcCtD
Esomeprazole—Weight increased—Hydroxyurea—head and neck cancer	0.000307	0.00532	CcSEcCtD
Esomeprazole—Infestation—Hydroxyurea—head and neck cancer	0.000301	0.00522	CcSEcCtD
Esomeprazole—Infestation NOS—Hydroxyurea—head and neck cancer	0.000301	0.00522	CcSEcCtD
Esomeprazole—Hypoaesthesia—Vinblastine—head and neck cancer	0.000295	0.00511	CcSEcCtD
Esomeprazole—Pharyngitis—Vinblastine—head and neck cancer	0.000294	0.0051	CcSEcCtD
Esomeprazole—Stomatitis—Hydroxyurea—head and neck cancer	0.000293	0.00508	CcSEcCtD
Esomeprazole—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000285	0.00493	CcSEcCtD
Esomeprazole—Osteoarthritis—Fluorouracil—head and neck cancer	0.000281	0.00487	CcSEcCtD
Esomeprazole—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000281	0.00487	CcSEcCtD
Esomeprazole—ATP4B—Ion channel transport—ATP7B—head and neck cancer	0.000281	0.0792	CbGpPWpGaD
Esomeprazole—Hepatocellular injury—Docetaxel—head and neck cancer	0.00028	0.00484	CcSEcCtD
Esomeprazole—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.00028	0.00484	CcSEcCtD
Esomeprazole—Blood pressure increased—Docetaxel—head and neck cancer	0.00028	0.00484	CcSEcCtD
Esomeprazole—Injection site reaction—Docetaxel—head and neck cancer	0.000278	0.00482	CcSEcCtD
Esomeprazole—Hallucination—Hydroxyurea—head and neck cancer	0.000269	0.00466	CcSEcCtD
Esomeprazole—Irritability—Fluorouracil—head and neck cancer	0.000268	0.00465	CcSEcCtD
Esomeprazole—Candida infection—Docetaxel—head and neck cancer	0.000267	0.00462	CcSEcCtD
Esomeprazole—Fluid retention—Docetaxel—head and neck cancer	0.000265	0.0046	CcSEcCtD
Esomeprazole—Alopecia—Vinblastine—head and neck cancer	0.000262	0.00454	CcSEcCtD
Esomeprazole—Dry skin—Fluorouracil—head and neck cancer	0.000258	0.00447	CcSEcCtD
Esomeprazole—Oesophagitis—Docetaxel—head and neck cancer	0.000255	0.00443	CcSEcCtD
Esomeprazole—Neoplasm—Docetaxel—head and neck cancer	0.000253	0.00438	CcSEcCtD
Esomeprazole—ATP4A—Ion channel transport—ATP7B—head and neck cancer	0.000251	0.0706	CbGpPWpGaD
Esomeprazole—Lightheadedness—Docetaxel—head and neck cancer	0.00025	0.00433	CcSEcCtD
Esomeprazole—Muscular weakness—Fluorouracil—head and neck cancer	0.000248	0.0043	CcSEcCtD
Esomeprazole—Dysphagia—Fluorouracil—head and neck cancer	0.000243	0.00421	CcSEcCtD
Esomeprazole—Chills—Hydroxyurea—head and neck cancer	0.000243	0.0042	CcSEcCtD
Esomeprazole—Ill-defined disorder—Vinblastine—head and neck cancer	0.000239	0.00415	CcSEcCtD
Esomeprazole—Alopecia—Hydroxyurea—head and neck cancer	0.000239	0.00414	CcSEcCtD
Esomeprazole—Anaemia—Vinblastine—head and neck cancer	0.000238	0.00413	CcSEcCtD
Esomeprazole—Angina pectoris—Fluorouracil—head and neck cancer	0.000237	0.0041	CcSEcCtD
Esomeprazole—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000233	0.00404	CcSEcCtD
Esomeprazole—Malaise—Vinblastine—head and neck cancer	0.000233	0.00403	CcSEcCtD
Esomeprazole—Vertigo—Vinblastine—head and neck cancer	0.000232	0.00402	CcSEcCtD
Esomeprazole—Leukopenia—Vinblastine—head and neck cancer	0.000231	0.004	CcSEcCtD
Esomeprazole—Pancytopenia—Fluorouracil—head and neck cancer	0.000231	0.004	CcSEcCtD
Esomeprazole—Swelling—Docetaxel—head and neck cancer	0.00023	0.00399	CcSEcCtD
Esomeprazole—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000226	0.00391	CcSEcCtD
Esomeprazole—Hepatic failure—Docetaxel—head and neck cancer	0.000226	0.00391	CcSEcCtD
Esomeprazole—Hypertension—Vinblastine—head and neck cancer	0.000223	0.00386	CcSEcCtD
Esomeprazole—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000222	0.00384	CcSEcCtD
Esomeprazole—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000218	0.00378	CcSEcCtD
Esomeprazole—Anaemia—Hydroxyurea—head and neck cancer	0.000217	0.00377	CcSEcCtD
Esomeprazole—Discomfort—Vinblastine—head and neck cancer	0.000217	0.00376	CcSEcCtD
Esomeprazole—Hot flush—Docetaxel—head and neck cancer	0.000217	0.00376	CcSEcCtD
Esomeprazole—Infestation NOS—Fluorouracil—head and neck cancer	0.000217	0.00375	CcSEcCtD
Esomeprazole—Infestation—Fluorouracil—head and neck cancer	0.000217	0.00375	CcSEcCtD
Esomeprazole—Menopausal symptoms—Docetaxel—head and neck cancer	0.000215	0.00373	CcSEcCtD
Esomeprazole—Visual disturbance—Docetaxel—head and neck cancer	0.000214	0.00371	CcSEcCtD
Esomeprazole—Renal impairment—Docetaxel—head and neck cancer	0.000213	0.00369	CcSEcCtD
Esomeprazole—Malaise—Hydroxyurea—head and neck cancer	0.000212	0.00368	CcSEcCtD
Esomeprazole—ATP4A—head—head and neck cancer	0.000212	0.0641	CbGeAlD
Esomeprazole—Stomatitis—Fluorouracil—head and neck cancer	0.000211	0.00366	CcSEcCtD
Esomeprazole—Conjunctivitis—Fluorouracil—head and neck cancer	0.000211	0.00365	CcSEcCtD
Esomeprazole—Urinary tract infection—Fluorouracil—head and neck cancer	0.000211	0.00365	CcSEcCtD
Esomeprazole—Leukopenia—Hydroxyurea—head and neck cancer	0.000211	0.00365	CcSEcCtD
Esomeprazole—Thrombocytopenia—Vinblastine—head and neck cancer	0.000206	0.00357	CcSEcCtD
Esomeprazole—Epistaxis—Fluorouracil—head and neck cancer	0.000204	0.00354	CcSEcCtD
Esomeprazole—Hyponatraemia—Docetaxel—head and neck cancer	0.000204	0.00353	CcSEcCtD
Esomeprazole—Sinusitis—Fluorouracil—head and neck cancer	0.000203	0.00352	CcSEcCtD
Esomeprazole—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000203	0.00352	CcSEcCtD
Esomeprazole—Pain in extremity—Docetaxel—head and neck cancer	0.000203	0.00352	CcSEcCtD
Esomeprazole—Agranulocytosis—Fluorouracil—head and neck cancer	0.000202	0.0035	CcSEcCtD
Esomeprazole—Anorexia—Vinblastine—head and neck cancer	0.000201	0.00348	CcSEcCtD
Esomeprazole—Migraine—Docetaxel—head and neck cancer	0.0002	0.00346	CcSEcCtD
Esomeprazole—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000199	0.00345	CcSEcCtD
Esomeprazole—Discomfort—Hydroxyurea—head and neck cancer	0.000198	0.00343	CcSEcCtD
Esomeprazole—Rhinitis—Fluorouracil—head and neck cancer	0.000195	0.00338	CcSEcCtD
Esomeprazole—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000194	0.00335	CcSEcCtD
Esomeprazole—Pharyngitis—Fluorouracil—head and neck cancer	0.000193	0.00335	CcSEcCtD
Esomeprazole—Infection—Hydroxyurea—head and neck cancer	0.000191	0.0033	CcSEcCtD
Esomeprazole—Paraesthesia—Vinblastine—head and neck cancer	0.000189	0.00328	CcSEcCtD
Esomeprazole—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000188	0.00326	CcSEcCtD
Esomeprazole—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000188	0.00326	CcSEcCtD
Esomeprazole—Skin disorder—Hydroxyurea—head and neck cancer	0.000187	0.00323	CcSEcCtD
Esomeprazole—Dry skin—Docetaxel—head and neck cancer	0.000186	0.00322	CcSEcCtD
Esomeprazole—Abdominal pain upper—Docetaxel—head and neck cancer	0.000185	0.00321	CcSEcCtD
Esomeprazole—Breast disorder—Docetaxel—head and neck cancer	0.000183	0.00318	CcSEcCtD
Esomeprazole—Anorexia—Hydroxyurea—head and neck cancer	0.000183	0.00317	CcSEcCtD
Esomeprazole—Decreased appetite—Vinblastine—head and neck cancer	0.000183	0.00317	CcSEcCtD
Esomeprazole—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000183	0.00317	CcSEcCtD
Esomeprazole—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000183	0.00317	CcSEcCtD
Esomeprazole—Cramp muscle—Docetaxel—head and neck cancer	0.000183	0.00317	CcSEcCtD
Esomeprazole—Pain—Vinblastine—head and neck cancer	0.00018	0.00312	CcSEcCtD
Esomeprazole—Constipation—Vinblastine—head and neck cancer	0.00018	0.00312	CcSEcCtD
Esomeprazole—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000179	0.0031	CcSEcCtD
Esomeprazole—Dysphagia—Docetaxel—head and neck cancer	0.000175	0.00304	CcSEcCtD
Esomeprazole—Feeling abnormal—Vinblastine—head and neck cancer	0.000174	0.00301	CcSEcCtD
Esomeprazole—Bronchospasm—Docetaxel—head and neck cancer	0.000173	0.00299	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000172	0.00298	CcSEcCtD
Esomeprazole—Alopecia—Fluorouracil—head and neck cancer	0.000172	0.00298	CcSEcCtD
Esomeprazole—Dyspnoea—Hydroxyurea—head and neck cancer	0.000171	0.00297	CcSEcCtD
Esomeprazole—Angina pectoris—Docetaxel—head and neck cancer	0.000171	0.00296	CcSEcCtD
Esomeprazole—Somnolence—Hydroxyurea—head and neck cancer	0.000171	0.00296	CcSEcCtD
Esomeprazole—Dyspepsia—Hydroxyurea—head and neck cancer	0.000169	0.00293	CcSEcCtD
Esomeprazole—Decreased appetite—Hydroxyurea—head and neck cancer	0.000167	0.00289	CcSEcCtD
Esomeprazole—Pancytopenia—Docetaxel—head and neck cancer	0.000167	0.00289	CcSEcCtD
Esomeprazole—Abdominal pain—Vinblastine—head and neck cancer	0.000166	0.00288	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000166	0.00287	CcSEcCtD
Esomeprazole—Fatigue—Hydroxyurea—head and neck cancer	0.000166	0.00287	CcSEcCtD
Esomeprazole—Pain—Hydroxyurea—head and neck cancer	0.000164	0.00284	CcSEcCtD
Esomeprazole—Constipation—Hydroxyurea—head and neck cancer	0.000164	0.00284	CcSEcCtD
Esomeprazole—Neutropenia—Docetaxel—head and neck cancer	0.000164	0.00284	CcSEcCtD
Esomeprazole—Weight increased—Docetaxel—head and neck cancer	0.00016	0.00277	CcSEcCtD
Esomeprazole—Vision blurred—Fluorouracil—head and neck cancer	0.00016	0.00277	CcSEcCtD
Esomeprazole—Weight decreased—Docetaxel—head and neck cancer	0.000159	0.00275	CcSEcCtD
Esomeprazole—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000158	0.00274	CcSEcCtD
Esomeprazole—Anaemia—Fluorouracil—head and neck cancer	0.000157	0.00271	CcSEcCtD
Esomeprazole—Infestation NOS—Docetaxel—head and neck cancer	0.000156	0.00271	CcSEcCtD
Esomeprazole—Infestation—Docetaxel—head and neck cancer	0.000156	0.00271	CcSEcCtD
Esomeprazole—Hypersensitivity—Vinblastine—head and neck cancer	0.000155	0.00269	CcSEcCtD
Esomeprazole—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000155	0.00269	CcSEcCtD
Esomeprazole—Renal failure—Docetaxel—head and neck cancer	0.000154	0.00266	CcSEcCtD
Esomeprazole—Jaundice—Docetaxel—head and neck cancer	0.000152	0.00264	CcSEcCtD
Esomeprazole—Stomatitis—Docetaxel—head and neck cancer	0.000152	0.00264	CcSEcCtD
Esomeprazole—Conjunctivitis—Docetaxel—head and neck cancer	0.000152	0.00263	CcSEcCtD
Esomeprazole—Body temperature increased—Hydroxyurea—head and neck cancer	0.000152	0.00263	CcSEcCtD
Esomeprazole—Leukopenia—Fluorouracil—head and neck cancer	0.000152	0.00263	CcSEcCtD
Esomeprazole—Asthenia—Vinblastine—head and neck cancer	0.000151	0.00262	CcSEcCtD
Esomeprazole—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000148	0.00256	CcSEcCtD
Esomeprazole—Epistaxis—Docetaxel—head and neck cancer	0.000148	0.00256	CcSEcCtD
Esomeprazole—Agranulocytosis—Docetaxel—head and neck cancer	0.000146	0.00253	CcSEcCtD
Esomeprazole—Chest pain—Fluorouracil—head and neck cancer	0.000144	0.0025	CcSEcCtD
Esomeprazole—Myalgia—Fluorouracil—head and neck cancer	0.000144	0.0025	CcSEcCtD
Esomeprazole—Diarrhoea—Vinblastine—head and neck cancer	0.000144	0.0025	CcSEcCtD
Esomeprazole—Discomfort—Fluorouracil—head and neck cancer	0.000142	0.00247	CcSEcCtD
Esomeprazole—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000141	0.00245	CcSEcCtD
Esomeprazole—Rhinitis—Docetaxel—head and neck cancer	0.000141	0.00244	CcSEcCtD
Esomeprazole—Hepatitis—Docetaxel—head and neck cancer	0.00014	0.00243	CcSEcCtD
Esomeprazole—Hypoaesthesia—Docetaxel—head and neck cancer	0.00014	0.00242	CcSEcCtD
Esomeprazole—Confusional state—Fluorouracil—head and neck cancer	0.000139	0.00241	CcSEcCtD
Esomeprazole—Pharyngitis—Docetaxel—head and neck cancer	0.000139	0.00241	CcSEcCtD
Esomeprazole—Dizziness—Vinblastine—head and neck cancer	0.000139	0.00241	CcSEcCtD
Esomeprazole—Urinary tract disorder—Docetaxel—head and neck cancer	0.000139	0.0024	CcSEcCtD
Esomeprazole—Oedema peripheral—Docetaxel—head and neck cancer	0.000138	0.0024	CcSEcCtD
Esomeprazole—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000138	0.00239	CcSEcCtD
Esomeprazole—Connective tissue disorder—Docetaxel—head and neck cancer	0.000138	0.00239	CcSEcCtD
Esomeprazole—Asthenia—Hydroxyurea—head and neck cancer	0.000138	0.00239	CcSEcCtD
Esomeprazole—Urethral disorder—Docetaxel—head and neck cancer	0.000138	0.00238	CcSEcCtD
Esomeprazole—Infection—Fluorouracil—head and neck cancer	0.000137	0.00238	CcSEcCtD
Esomeprazole—Nervous system disorder—Fluorouracil—head and neck cancer	0.000136	0.00235	CcSEcCtD
Esomeprazole—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000135	0.00234	CcSEcCtD
Esomeprazole—Visual impairment—Docetaxel—head and neck cancer	0.000135	0.00234	CcSEcCtD
Esomeprazole—Tachycardia—Fluorouracil—head and neck cancer	0.000135	0.00234	CcSEcCtD
Esomeprazole—Vomiting—Vinblastine—head and neck cancer	0.000134	0.00232	CcSEcCtD
Esomeprazole—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.000133	0.0375	CbGpPWpGaD
Esomeprazole—Erythema multiforme—Docetaxel—head and neck cancer	0.000133	0.0023	CcSEcCtD
Esomeprazole—Headache—Vinblastine—head and neck cancer	0.000132	0.00229	CcSEcCtD
Esomeprazole—Anorexia—Fluorouracil—head and neck cancer	0.000132	0.00228	CcSEcCtD
Esomeprazole—Diarrhoea—Hydroxyurea—head and neck cancer	0.000131	0.00228	CcSEcCtD
Esomeprazole—Eye disorder—Docetaxel—head and neck cancer	0.000131	0.00227	CcSEcCtD
Esomeprazole—Flushing—Docetaxel—head and neck cancer	0.00013	0.00226	CcSEcCtD
Esomeprazole—Dizziness—Hydroxyurea—head and neck cancer	0.000127	0.0022	CcSEcCtD
Esomeprazole—Immune system disorder—Docetaxel—head and neck cancer	0.000127	0.0022	CcSEcCtD
Esomeprazole—Mediastinal disorder—Docetaxel—head and neck cancer	0.000127	0.00219	CcSEcCtD
Esomeprazole—Chills—Docetaxel—head and neck cancer	0.000126	0.00218	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000126	0.00218	CcSEcCtD
Esomeprazole—Nausea—Vinblastine—head and neck cancer	0.000125	0.00217	CcSEcCtD
Esomeprazole—Insomnia—Fluorouracil—head and neck cancer	0.000125	0.00217	CcSEcCtD
Esomeprazole—Paraesthesia—Fluorouracil—head and neck cancer	0.000124	0.00215	CcSEcCtD
Esomeprazole—Alopecia—Docetaxel—head and neck cancer	0.000124	0.00215	CcSEcCtD
Esomeprazole—Dyspnoea—Fluorouracil—head and neck cancer	0.000123	0.00213	CcSEcCtD
Esomeprazole—Mental disorder—Docetaxel—head and neck cancer	0.000123	0.00213	CcSEcCtD
Esomeprazole—Somnolence—Fluorouracil—head and neck cancer	0.000123	0.00213	CcSEcCtD
Esomeprazole—Malnutrition—Docetaxel—head and neck cancer	0.000122	0.00212	CcSEcCtD
Esomeprazole—Vomiting—Hydroxyurea—head and neck cancer	0.000122	0.00212	CcSEcCtD
Esomeprazole—Dyspepsia—Fluorouracil—head and neck cancer	0.000122	0.00211	CcSEcCtD
Esomeprazole—Rash—Hydroxyurea—head and neck cancer	0.000121	0.0021	CcSEcCtD
Esomeprazole—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.000121	0.0341	CbGpPWpGaD
Esomeprazole—Dermatitis—Hydroxyurea—head and neck cancer	0.000121	0.0021	CcSEcCtD
Esomeprazole—Headache—Hydroxyurea—head and neck cancer	0.00012	0.00208	CcSEcCtD
Esomeprazole—Decreased appetite—Fluorouracil—head and neck cancer	0.00012	0.00208	CcSEcCtD
Esomeprazole—Dysgeusia—Docetaxel—head and neck cancer	0.00012	0.00207	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000119	0.00207	CcSEcCtD
Esomeprazole—Back pain—Docetaxel—head and neck cancer	0.000118	0.00205	CcSEcCtD
Esomeprazole—Pain—Fluorouracil—head and neck cancer	0.000118	0.00205	CcSEcCtD
Esomeprazole—Muscle spasms—Docetaxel—head and neck cancer	0.000118	0.00204	CcSEcCtD
Esomeprazole—Nausea—Hydroxyurea—head and neck cancer	0.000114	0.00198	CcSEcCtD
Esomeprazole—Feeling abnormal—Fluorouracil—head and neck cancer	0.000114	0.00197	CcSEcCtD
Esomeprazole—Anaemia—Docetaxel—head and neck cancer	0.000113	0.00196	CcSEcCtD
Esomeprazole—Urticaria—Fluorouracil—head and neck cancer	0.00011	0.0019	CcSEcCtD
Esomeprazole—Leukopenia—Docetaxel—head and neck cancer	0.000109	0.0019	CcSEcCtD
Esomeprazole—Body temperature increased—Fluorouracil—head and neck cancer	0.000109	0.00189	CcSEcCtD
Esomeprazole—Palpitations—Docetaxel—head and neck cancer	0.000108	0.00187	CcSEcCtD
Esomeprazole—Cough—Docetaxel—head and neck cancer	0.000107	0.00185	CcSEcCtD
Esomeprazole—Hypertension—Docetaxel—head and neck cancer	0.000106	0.00183	CcSEcCtD
Esomeprazole—Myalgia—Docetaxel—head and neck cancer	0.000104	0.0018	CcSEcCtD
Esomeprazole—Chest pain—Docetaxel—head and neck cancer	0.000104	0.0018	CcSEcCtD
Esomeprazole—Arthralgia—Docetaxel—head and neck cancer	0.000104	0.0018	CcSEcCtD
Esomeprazole—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000103	0.00179	CcSEcCtD
Esomeprazole—Hypersensitivity—Fluorouracil—head and neck cancer	0.000102	0.00176	CcSEcCtD
Esomeprazole—Dry mouth—Docetaxel—head and neck cancer	0.000102	0.00176	CcSEcCtD
Esomeprazole—Confusional state—Docetaxel—head and neck cancer	0.000101	0.00174	CcSEcCtD
Esomeprazole—Anaphylactic shock—Docetaxel—head and neck cancer	9.98e-05	0.00173	CcSEcCtD
Esomeprazole—Infection—Docetaxel—head and neck cancer	9.91e-05	0.00172	CcSEcCtD
Esomeprazole—Shock—Docetaxel—head and neck cancer	9.81e-05	0.0017	CcSEcCtD
Esomeprazole—Nervous system disorder—Docetaxel—head and neck cancer	9.78e-05	0.00169	CcSEcCtD
Esomeprazole—ATP4B—Transmembrane transport of small molecules—ATP7B—head and neck cancer	9.78e-05	0.0276	CbGpPWpGaD
Esomeprazole—Pruritus—Fluorouracil—head and neck cancer	9.78e-05	0.00169	CcSEcCtD
Esomeprazole—Thrombocytopenia—Docetaxel—head and neck cancer	9.77e-05	0.00169	CcSEcCtD
Esomeprazole—Tachycardia—Docetaxel—head and neck cancer	9.74e-05	0.00169	CcSEcCtD
Esomeprazole—Skin disorder—Docetaxel—head and neck cancer	9.69e-05	0.00168	CcSEcCtD
Esomeprazole—Anorexia—Docetaxel—head and neck cancer	9.51e-05	0.00165	CcSEcCtD
Esomeprazole—Diarrhoea—Fluorouracil—head and neck cancer	9.46e-05	0.00164	CcSEcCtD
Esomeprazole—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	9.39e-05	0.0265	CbGpPWpGaD
Esomeprazole—Dizziness—Fluorouracil—head and neck cancer	9.14e-05	0.00158	CcSEcCtD
Esomeprazole—Musculoskeletal discomfort—Docetaxel—head and neck cancer	9.09e-05	0.00157	CcSEcCtD
Esomeprazole—Insomnia—Docetaxel—head and neck cancer	9.02e-05	0.00156	CcSEcCtD
Esomeprazole—Paraesthesia—Docetaxel—head and neck cancer	8.96e-05	0.00155	CcSEcCtD
Esomeprazole—Dyspnoea—Docetaxel—head and neck cancer	8.89e-05	0.00154	CcSEcCtD
Esomeprazole—Somnolence—Docetaxel—head and neck cancer	8.87e-05	0.00154	CcSEcCtD
Esomeprazole—Vomiting—Fluorouracil—head and neck cancer	8.79e-05	0.00152	CcSEcCtD
Esomeprazole—Dyspepsia—Docetaxel—head and neck cancer	8.78e-05	0.00152	CcSEcCtD
Esomeprazole—ATP4A—Transmembrane transport of small molecules—ATP7B—head and neck cancer	8.72e-05	0.0246	CbGpPWpGaD
Esomeprazole—Rash—Fluorouracil—head and neck cancer	8.71e-05	0.00151	CcSEcCtD
Esomeprazole—Dermatitis—Fluorouracil—head and neck cancer	8.71e-05	0.00151	CcSEcCtD
Esomeprazole—Decreased appetite—Docetaxel—head and neck cancer	8.67e-05	0.0015	CcSEcCtD
Esomeprazole—Headache—Fluorouracil—head and neck cancer	8.66e-05	0.0015	CcSEcCtD
Esomeprazole—Gastrointestinal disorder—Docetaxel—head and neck cancer	8.61e-05	0.00149	CcSEcCtD
Esomeprazole—Fatigue—Docetaxel—head and neck cancer	8.6e-05	0.00149	CcSEcCtD
Esomeprazole—Constipation—Docetaxel—head and neck cancer	8.53e-05	0.00148	CcSEcCtD
Esomeprazole—Pain—Docetaxel—head and neck cancer	8.53e-05	0.00148	CcSEcCtD
Esomeprazole—Feeling abnormal—Docetaxel—head and neck cancer	8.22e-05	0.00142	CcSEcCtD
Esomeprazole—Nausea—Fluorouracil—head and neck cancer	8.21e-05	0.00142	CcSEcCtD
Esomeprazole—Gastrointestinal pain—Docetaxel—head and neck cancer	8.16e-05	0.00141	CcSEcCtD
Esomeprazole—Abdominal pain—Docetaxel—head and neck cancer	7.89e-05	0.00137	CcSEcCtD
Esomeprazole—Body temperature increased—Docetaxel—head and neck cancer	7.89e-05	0.00137	CcSEcCtD
Esomeprazole—Hypersensitivity—Docetaxel—head and neck cancer	7.35e-05	0.00127	CcSEcCtD
Esomeprazole—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	7.28e-05	0.0205	CbGpPWpGaD
Esomeprazole—Asthenia—Docetaxel—head and neck cancer	7.16e-05	0.00124	CcSEcCtD
Esomeprazole—Pruritus—Docetaxel—head and neck cancer	7.06e-05	0.00122	CcSEcCtD
Esomeprazole—Diarrhoea—Docetaxel—head and neck cancer	6.83e-05	0.00118	CcSEcCtD
Esomeprazole—Dizziness—Docetaxel—head and neck cancer	6.6e-05	0.00114	CcSEcCtD
Esomeprazole—CYP2C19—Xenobiotics—CYP1A1—head and neck cancer	6.39e-05	0.018	CbGpPWpGaD
Esomeprazole—Vomiting—Docetaxel—head and neck cancer	6.34e-05	0.0011	CcSEcCtD
Esomeprazole—Rash—Docetaxel—head and neck cancer	6.29e-05	0.00109	CcSEcCtD
Esomeprazole—Dermatitis—Docetaxel—head and neck cancer	6.28e-05	0.00109	CcSEcCtD
Esomeprazole—Headache—Docetaxel—head and neck cancer	6.25e-05	0.00108	CcSEcCtD
Esomeprazole—CYP2C19—Tamoxifen metabolism—CYP1A1—head and neck cancer	6.15e-05	0.0173	CbGpPWpGaD
Esomeprazole—Nausea—Docetaxel—head and neck cancer	5.93e-05	0.00103	CcSEcCtD
Esomeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	4.91e-05	0.0138	CbGpPWpGaD
Esomeprazole—CYP2C19—Melatonin metabolism and effects—CYP1A1—head and neck cancer	4.75e-05	0.0134	CbGpPWpGaD
Esomeprazole—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	4.59e-05	0.0129	CbGpPWpGaD
Esomeprazole—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	4.41e-05	0.0124	CbGpPWpGaD
Esomeprazole—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	4.18e-05	0.0118	CbGpPWpGaD
Esomeprazole—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	3.84e-05	0.0108	CbGpPWpGaD
Esomeprazole—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	3.7e-05	0.0104	CbGpPWpGaD
Esomeprazole—CYP2C19—Arachidonic acid metabolism—GPX1—head and neck cancer	3.1e-05	0.00874	CbGpPWpGaD
Esomeprazole—CYP2C19—Arachidonic acid metabolism—CYP1A1—head and neck cancer	3.07e-05	0.00865	CbGpPWpGaD
Esomeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	2.65e-05	0.00748	CbGpPWpGaD
Esomeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	2.62e-05	0.00738	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—NAT2—head and neck cancer	2.44e-05	0.00688	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—NAT2—head and neck cancer	2.41e-05	0.00678	CbGpPWpGaD
Esomeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	2.15e-05	0.00606	CbGpPWpGaD
Esomeprazole—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	1.97e-05	0.00556	CbGpPWpGaD
Esomeprazole—CYP2C19—Arachidonic acid metabolism—PTGS2—head and neck cancer	1.83e-05	0.00514	CbGpPWpGaD
Esomeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	1.6e-05	0.0045	CbGpPWpGaD
Esomeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	1.57e-05	0.00444	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—NAT2—head and neck cancer	1.47e-05	0.00414	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	1.45e-05	0.00408	CbGpPWpGaD
Esomeprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	1.29e-05	0.00364	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—GSTM1—head and neck cancer	1.21e-05	0.0034	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—GSTM1—head and neck cancer	1.19e-05	0.00335	CbGpPWpGaD
Esomeprazole—CYP2C19—Biological oxidations—CYP1A1—head and neck cancer	1.14e-05	0.00322	CbGpPWpGaD
Esomeprazole—CYP2C19—Metapathway biotransformation—CYP1A1—head and neck cancer	1.13e-05	0.00318	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—UROD—head and neck cancer	1.01e-05	0.00283	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	7.8e-06	0.0022	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	7.25e-06	0.00204	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	7.15e-06	0.00201	CbGpPWpGaD
Esomeprazole—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	6.87e-06	0.00194	CbGpPWpGaD
Esomeprazole—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	6.78e-06	0.00191	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—UROD—head and neck cancer	6.04e-06	0.0017	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	4.43e-06	0.00125	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	4.39e-06	0.00124	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—NAT2—head and neck cancer	4.17e-06	0.00118	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—DPYD—head and neck cancer	3.66e-06	0.00103	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—YAP1—head and neck cancer	3.47e-06	0.000978	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.61e-06	0.000735	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—NAT2—head and neck cancer	2.51e-06	0.000707	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.28e-06	0.000641	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—DPYD—head and neck cancer	2.2e-06	0.00062	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—YAP1—head and neck cancer	2.09e-06	0.000588	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—TYMS—head and neck cancer	2.09e-06	0.000588	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GSTM1—head and neck cancer	2.06e-06	0.000581	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—GPX1—head and neck cancer	1.97e-06	0.000556	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—CYP1A1—head and neck cancer	1.95e-06	0.000551	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.61e-06	0.000452	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—TYMS—head and neck cancer	1.25e-06	0.000353	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.24e-06	0.000349	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—GPX1—head and neck cancer	1.19e-06	0.000334	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.18e-06	0.000331	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PTGS2—head and neck cancer	1.16e-06	0.000327	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PTEN—head and neck cancer	1.01e-06	0.000286	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—PIK3CA—head and neck cancer	7.15e-07	0.000201	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PTGS2—head and neck cancer	6.99e-07	0.000197	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PTEN—head and neck cancer	6.09e-07	0.000172	CbGpPWpGaD
Esomeprazole—CYP2C19—Metabolism—AKT1—head and neck cancer	5.84e-07	0.000165	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—PIK3CA—head and neck cancer	4.3e-07	0.000121	CbGpPWpGaD
Esomeprazole—CYP3A4—Metabolism—AKT1—head and neck cancer	3.51e-07	9.9e-05	CbGpPWpGaD
